Five Chinese COVID-19 vaccines undergo phase-III clinical trials overseas: MOFA

26

Five Chinese COVID-19 vaccine candidates are under phase-III clinical trials in countries including the UAE, Brazil, Pakistan and Peru, according to Foreign Ministry Spokesperson Zhao Lijian on Wednesday.

He introduced that the five Chinese vaccines are: two inactivated vaccines developed by the China National Pharmaceutical Group (Sinopharm), one inactivated vaccine developed by Sinovac Biotech Co., one adenoviral vector vaccine jointly developed by the Academy of Military Sciences and the Chinese biotech company CanSino, and one recombinant protein vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy.

“After the pandemic broke out, the Chinese government at the earliest time possible laid out five technical routes including inactivated vaccine, recombinant protein vaccine, adenoviral vector vaccine, attenuated influenza vaccine and nucleic acid vaccine,” Zhao said.

Leave A Reply

Your email address will not be published.